These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
869 related articles for article (PubMed ID: 32422527)
21. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401 [TBL] [Abstract][Full Text] [Related]
22. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566 [TBL] [Abstract][Full Text] [Related]
23. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8 Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667 [TBL] [Abstract][Full Text] [Related]
24. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related]
25. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464 [TBL] [Abstract][Full Text] [Related]
26. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403 [TBL] [Abstract][Full Text] [Related]
27. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814 [TBL] [Abstract][Full Text] [Related]
28. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S Front Immunol; 2018; 9():1955. PubMed ID: 30214445 [No Abstract] [Full Text] [Related]
31. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model. Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS Front Immunol; 2021; 12():737076. PubMed ID: 34659228 [TBL] [Abstract][Full Text] [Related]
32. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. Cui X; Jia H; Xin H; Zhang L; Chen S; Xia S; Li X; Xu W; Chen X; Feng Y; Wei X; Yu H; Wang Y; Zhan Y; Zhu X; Zhang X Front Immunol; 2021; 12():778978. PubMed ID: 34925354 [TBL] [Abstract][Full Text] [Related]
33. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment. Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045 [TBL] [Abstract][Full Text] [Related]
34. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112 [TBL] [Abstract][Full Text] [Related]
35. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929 [TBL] [Abstract][Full Text] [Related]
36. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS Front Immunol; 2020; 11():7. PubMed ID: 32117218 [TBL] [Abstract][Full Text] [Related]
37. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624 [TBL] [Abstract][Full Text] [Related]